Mark Uhlik

4.0k total citations
50 papers, 1.9k citations indexed

About

Mark Uhlik is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Mark Uhlik has authored 50 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 20 papers in Oncology and 13 papers in Immunology. Recurrent topics in Mark Uhlik's work include Angiogenesis and VEGF in Cancer (11 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Immunotherapy and Immune Responses (6 papers). Mark Uhlik is often cited by papers focused on Angiogenesis and VEGF in Cancer (11 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Immunotherapy and Immune Responses (6 papers). Mark Uhlik collaborates with scholars based in United States, South Korea and Germany. Mark Uhlik's co-authors include Gary L. Johnson, Amy N. Abell, Bruce D. Cuevas, Nancy L. Johnson, Shao‐Cong Sun, Edward W. Harhaj, Jonathan A. Lee, Gutian Xiao, Eric A. Horne and David P. Siderovski and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Mark Uhlik

50 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Uhlik United States	17	907	456	429	323	276	50	1.9k
Christopher S. Hackett United States	18	1.1k 1.2×	504 1.1×	1.1k 2.6×	227 0.7×	206 0.7×	25	2.3k
Jiyang Yu United States	21	1.8k 1.9×	491 1.1×	511 1.2×	305 0.9×	82 0.3×	74	2.5k
Kerry Kelleher United States	18	831 0.9×	484 1.1×	321 0.7×	104 0.3×	109 0.4×	26	1.8k
Hsiu-Ming Shih Taiwan	26	1.8k 2.0×	421 0.9×	523 1.2×	353 1.1×	46 0.2×	44	2.3k
Qingrong Chen United States	25	1.3k 1.4×	240 0.5×	388 0.9×	450 1.4×	306 1.1×	61	2.0k
Françesc Canals Spain	28	1.5k 1.7×	285 0.6×	420 1.0×	278 0.9×	83 0.3×	97	2.5k
Sarah Hanrahan United Kingdom	17	1.2k 1.3×	205 0.4×	234 0.5×	370 1.1×	90 0.3×	24	1.8k
Scott R. Frank United States	17	2.5k 2.7×	244 0.5×	622 1.4×	321 1.0×	59 0.2×	20	3.0k
Donald J. Fujita Canada	26	2.1k 2.3×	443 1.0×	625 1.5×	265 0.8×	39 0.1×	46	2.8k
Man‐Sun Sy United States	33	2.7k 3.0×	303 0.7×	278 0.6×	170 0.5×	110 0.4×	66	3.3k

Countries citing papers authored by Mark Uhlik

Since Specialization

Citations

This map shows the geographic impact of Mark Uhlik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Uhlik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Uhlik more than expected).

Fields of papers citing papers by Mark Uhlik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Uhlik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Uhlik. The network helps show where Mark Uhlik may publish in the future.

Co-authorship network of co-authors of Mark Uhlik

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Uhlik. A scholar is included among the top collaborators of Mark Uhlik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Uhlik. Mark Uhlik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thomas, Stacy K., Max M. Wattenberg, Mark Uhlik, et al.. (2023). Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice. Nature Communications. 14(1). 6330–6330. 20 indexed citations

Kim, Dae Won, Mokenge P. Malafa, Rutika Mehta, et al.. (2023). RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and Nivolumab. Oncology. 102(7). 549–555. 1 indexed citations

Uhlik, Mark, Seema Iyer, Luka Ausec, et al.. (2023). Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers. Frontiers in Oncology. 13. 1158345–1158345. 3 indexed citations

Chan, Anissa, Xiaohong Qiu, Mark Uhlik, et al.. (2022). Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies. Frontiers in Oncology. 12. 869078–869078. 15 indexed citations

Chan, Anissa, Nandita Bose, Richard M. Walsh, et al.. (2020). P862 Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with imprime PGG and pembrolizumab. Poster presentations. A10.1–A10. 2 indexed citations

Fischl, Anthony S., Xiaoen Wang, Beverly L. Falcón, et al.. (2019). Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition. Molecular Cancer Therapeutics. 18(4). 856–867. 16 indexed citations

Falcón, Beverly L., Sudhakar Chintharlapalli, Mark Uhlik, & Bronislaw Pytowski. (2016). Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents. Pharmacology & Therapeutics. 164. 204–225. 112 indexed citations

Peng, Sheng-Bin, Xiaoyi Zhang, Donald C. Paul, et al.. (2016). Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies. PLoS ONE. 11(3). e0150585–e0150585. 50 indexed citations

Peng, Sheng-Bin, Xiaoyi Zhang, Donald C. Paul, et al.. (2014). Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models. Molecular Cancer Therapeutics. 14(2). 480–490. 116 indexed citations

10.

Falcón, Beverly L., Michelle L. Swearingen, Wendy H. Gough, et al.. (2014). An In Vitro Cord Formation Assay Identifies Unique Vascular Phenotypes Associated with Angiogenic Growth Factors. PLoS ONE. 9(9). e106901–e106901. 8 indexed citations

11.

Willard, Melinda D., Mary E. Lajiness, Isabella H. Wulur, et al.. (2012). Somatic Mutations in CCK2R Alter Receptor Activity that Promote Oncogenic Phenotypes. Molecular Cancer Research. 10(6). 739–749. 15 indexed citations

12.

Lee, Jonathan A., Mark Uhlik, Christopher M. Moxham, Dirk Tomandl, & Daniel J. Sall. (2012). Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy. Journal of Medicinal Chemistry. 55(10). 4527–4538. 134 indexed citations

13.

Meier, Timothy I., Mark Uhlik, Sudhakar Chintharlapalli, et al.. (2011). Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization. Molecular Cancer Therapeutics. 10(11). 2168–2178. 31 indexed citations

14.

Francia, Giulio, Yuval Shaked, Kae Hashimoto, et al.. (2011). Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis. Molecular Cancer Therapeutics. 11(3). 680–689. 33 indexed citations

15.

Gough, Wendy H., et al.. (2011). A Quantitative, Facile, and High-Throughput Image-Based Cell Migration Method Is a Robust Alternative to the Scratch Assay. SLAS DISCOVERY. 16(2). 155–163. 64 indexed citations

16.

Yingling, Jonathan M., Jianyong Shou, Xiaoling Xia, et al.. (2006). A small molecule inhibitor of TGFβ RI kinase potentiates VEGF dependent angiogenesis in vitro. Cancer Research. 66. 59–59. 1 indexed citations

17.

Cuevas, Bruce D., Mark Uhlik, Timothy Garrington, & Gary L. Johnson. (2004). MEKK1 regulates the AP-1 dimer repertoire via control of JunB transcription and Fra-2 protein stability. Oncogene. 24(5). 801–809. 31 indexed citations

18.

Uhlik, Mark, Brenda Temple, Sompop Bencharit, et al.. (2004). Structural and Evolutionary Division of Phosphotyrosine Binding (PTB) Domains. Journal of Molecular Biology. 345(1). 1–20. 203 indexed citations

19.

Uhlik, Mark, Amy N. Abell, Nancy L. Johnson, et al.. (2003). Rac–MEKK3–MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nature Cell Biology. 5(12). 1104–1110. 310 indexed citations

20.

Maggirwar, Sanjay B., et al.. (1996). Multiple Structural Domains within IκBα Are Required for Its Inducible Degradation by both Cytokines and Phosphatase Inhibitors. Biochemical and Biophysical Research Communications. 223(1). 123–128. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact